Selected article for: "effective drug and structural protein"

Author: Parvez, Md. Sorwer Alam; Karim, Md. Adnan; Hasan, Mahmudul; Jaman, Jomana; Karim, Ziaul; Tahsin, Tohura; Hasan, Md. Nazmul; Hosen, Mohammad Jakir
Title: Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach
  • Cord-id: u54qh0zm
  • Document date: 2020_9_17
  • ID: u54qh0zm
    Snippet: The pandemic prevalence of COVID-19 has become a very serious global health issue. Scientists all over the world have been seriously attempting in the discovery of a drug to combat SARS-CoV-2. It has been found that RNA-dependent RNA polymerase (RdRp) plays a crucial role in SARS-CoV-2 replication, and thus could be a potential drug target. Here, comprehensive computational approaches including drug repurposing and molecular docking were employed to predict an effective drug candidate targeting
    Document: The pandemic prevalence of COVID-19 has become a very serious global health issue. Scientists all over the world have been seriously attempting in the discovery of a drug to combat SARS-CoV-2. It has been found that RNA-dependent RNA polymerase (RdRp) plays a crucial role in SARS-CoV-2 replication, and thus could be a potential drug target. Here, comprehensive computational approaches including drug repurposing and molecular docking were employed to predict an effective drug candidate targeting RdRp of SARS-CoV-2. This study revealed that Rifabutin, Rifapentine, Fidaxomicin, 7-methyl-guanosine-5′-triphosphate-5′-guanosine and Ivermectin have a potential inhibitory interaction with RdRp of SARS-CoV-2, and could be effective drugs for COVID-19. In addition, virtual screening of the compounds from ZINC database also allowed the prediction of two compounds (ZINC09128258 and ZINC09883305) with pharmacophore features that interact effectively with RdRp of SARS-CoV-2, indicating their potentiality as effective inhibitors of the enzyme. Furthermore, ADME analysis along with analysis of toxicity was also undertaken to check the pharmacokinetics and drug-likeness properties of the two compounds. Comparative structural analysis of protein-inhibitor complexes revealed that the amino acids Y32, K47, Y122, Y129, H133, N138, D140, T141, S709 and N781 are crucial for drug surface hotspot in the RdRp of SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and acute respiratory distress: 1, 2, 3
    • accessory protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accurate prediction and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • accurate prediction and acute respiratory distress: 1, 2, 3, 4
    • accurate prediction and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • accurate prediction and low efficacy: 1
    • acute respiratory and adme excretion metabolism distribution: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory and adme excretion metabolism distribution absorption: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory and adme property: 1, 2, 3, 4, 5
    • acute respiratory and long term solution: 1, 2, 3, 4
    • acute respiratory and low binding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low binding energy: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory and low efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress and low binding: 1, 2, 3, 4
    • acute respiratory distress and low binding energy: 1
    • acute respiratory distress and low efficacy: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and low binding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low binding energy: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and low efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23